Transdermal Drug Delivery - Technologies, Markets, and Companies
NEW YORK, Jan. 3, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Transdermal Drug Delivery - Technologies, Markets, and Companies
http://www.reportlinker.com/p0203552/Transdermal-Drug-Delivery---Technologies-Markets-and-Companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology
Benefits of this report
-Up-to-date one-stop information on transdermal drug delivery
-Description of 126 companies involved and 109 collaborations in this area
-Market analysis 2010-2020/
-Market values in major regions
-Strategies for developing markets for transdermal drug delivery
-A selected bibliography of 200 publications
-Text is supplemented by 18 tables and 10 figures
Who should read this report?
-Biotechnology companies developing transdermal technologies
-Drug delivery companies
-Pharmaceutical companies interested in transdermal drug delivery
-Pharmaceutical research institutes
Summary
This report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral,intravascular, subcutaneous and transmucosal routes. Various transdermal drug delivery technologies are described including the use of suitable formulations, carriers and penetration enhancers. The most commonly used transdermal system is the skin patch using various types of technologies. Nanoparticles as well as the use of physical agents to facilitate transcutaneous drug delivery is described. Microneedle and needleless technologies are also described. Transdermal technologies may be applied for several categories of pharmaceuticals used for the treatment of disorders of the skin or for systemic effect to treat diseases of other organs. Several transdermal products and applications include hormone replacement therapy, contraception, management of pain, angina pectoris, smoking cessation and neurological disorders such as Parkinson's disease. The market for transdermal drug delivery is analyzed according to technologies and therapeutic areas from 2011 to 2021. This market is analyzed according to geographical regions as well.
Table of Contents
0. Executive Summary 11
1. Basics of Transdermal Drug Delivery 13
Introduction 13
Historical landmarks in transdermal drug delivery 13
Anatomy and physiology of skin 14
Transcutaneous absorption 14
Transdermal versus other methods of drug delivery 14
Advantages of transdermal drug delivery 15
First-Pass Effect 15
Drawbacks of transdermal delivery 15
Factors that influence transdermal drug delivery 15
Events governing transcutaneous absorption 16
Properties of the skin 16
Properties of drugs 17
The role of pH and pharmacokinetics 17
Intradermal disposition of drugs after topical application 18
2. Transdermal Drug Delivery Technologies 19
Introduction 19
Local application formulations 20
Crystalline topical formulations 20
Microemulsions for transdermal drug delivery 20
Nanoemulsions for transdermal drug delivery 21
Transdermal gel technology 21
Film forming polymeric solutions 22
Biphasix system 23
Penetration enhancers 23
Chemical enhancers 23
Nitric oxide-based transdermal drug delivery 25
Vesicular transdermal carriers 25
Liposomes 26
Transfersomes 26
Ethosomes 27
Elastic vesicles for transdermal drug delivery 27
Nanovesicles for transdermal drug delivery 28
Transdermal patches 28
Adhesives for transdermal patches 29
Commercial development of transdermal patches 30
Innovations in transdermal patches 31
e-Patch™ controlled release micropump system 31
Patchless Transdermal Delivery System 32
Metered-dose transdermal system 32
Use of physical modalities to facilitate transdermal transport 33
Transdermal electrotransport 33
Electroporation 33
Drug delivery by electroporation 34
Cryoelectrophoresis 35
Iontophoresis 36
Iontophoresis compared with electrophoresis 37
Application of iontophoresis for drug delivery 37
Companies with technologies for drug delivery by iontophoresis 38
Combination of electrophoresis and iontophoresis 39
Dermaportation 39
Radiofrequency-driven transdermal delivery 39
Microporation 40
Transcutaneous drug delivery by electropulsation 40
Companies involved in electroporation-based drug delivery 41
Electrode Scanning System 41
Use of electrostatic force in skin patch technology 41
Multiple Absorption Kinetic System 42
Transdermal drug delivery facilitated by heat 42
Controlled, heat-aided drug delivery 42
Ultrasound 43
Magnetophoresis 45
Use of lasers for transdermal drug delivery 45
Transdermal drug delivery by laser-induced pressure waves 45
Transdermal drug delivery by laser-assisted changes in skin 45
Transdermal delivery by gas under pressure 46
Transdermal delivery with PowderJect gas gun 46
Microscission induced by gas 46
Microneedles and dermal microinjection technologies 47
Microneedle patch 47
Microneedle arrays for drug delivery 48
MicroPyramid™ hollow microneedles 48
Microstructured Transdermal Systems 49
Microneedle Array Patch technology 49
Macroflux microprojections technology 49
Companies developing microneedles for transdermal drug delivery 49
Needlefree injections 50
Glide SDI® solid dose injector 50
Jet injection 50
Mini-Ject needlefree delivery system 51
MicroJet for painless injections 51
Nanoliter-volume pulsed microjets 51
SUMAVEL™ DosePro™ needle-less injection 52
Skin ablation or abrasion for drug delivery 52
Nanotechnology-based transdermal drug delivery 52
Nanoparticles and nanoemulsions for skin disorders 53
Transdermal nanoparticle preparations for systemic effect 53
Nanotechnology-based transdermal vaccination and immunotherapy 54
Delivery of nanostructured drugs from transdermal patches 54
NanoCyte transdermal drug delivery system 54
Effect of mechanical flexion on penetration of bucky balls through the skin 55
Safety issues of applications of nanomaterial carriers on the skin 55
Comparison of transdermal drug delivery systems 55
Role of microelectronics in transdermal drug delivery 56
Transdermal drug design 56
In vitro testing of transdermal drug delivery systems 56
In vivo testing of drug delivery systems 57
Infrared spectroscopy for evaluation of transdermal drug delivery 58
Modeling of transport through the skin 58
Concluding remarks on transdermal drug delivery technologies 59
Future developments in transdermal drug delivery 59
3. Transdermal Therapeutics 61
Introduction 61
Drugs that can be administered transdermally 61
Skin disorders 64
Psoriasis 64
Nanoemulsions for paclitaxel delivery in psoriasis 64
Iontophoresis for treatment of psoriasis 64
Hair loss 64
Cardiovascular disorders 65
Angina pectoris 65
Transdermal drug delivery for hypertension 66
Transdermal beta blockers 66
Transdermal anticoagulants 67
Congestive heart failure 67
Respiratory diseases 67
Asthma 67
Chronic obstructive pulmonary disease 68
Neurological and psychiatric disorders 68
Parkinson's disease 68
Transdermal drug delivery for Parkinson's disease 69
Transdermal dopamine agonists for Parkinson's disease 69
Rotigotine 70
Transdermal administration of other drugs for Parkinson disease 72
Depression 72
Transdermal selegiline 72
Bipolar disorder 73
Transdermal lithium 73
Restless legs syndrome 73
Alzheimer's disease 73
Transdermal nicotine for Tourette syndrome 74
Attention deficit hyperactivity disorder 74
Transdermal methylphenidate 74
Migraine 75
Transdermal lidocaine 75
Transdermal sumatriptan 75
Epilepsy 76
Tinnitus/Vertigo 76
Transdermal nitroglycerin for vasospasm due to subarachnoid hemorrhage 76
Musculoskeletal disorders 76
Osteoporosis 76
Transdermal alendronate 77
Transdermal estrogen 77
Transdermal human parathyroid hormone 77
Osteoarthritis 77
Transdermal therapy of diabetes 78
Transdermal insulin delivery in diabetes 78
Transdermal GLP1 agonist 79
Male sexual disorders 79
Erectile dysfunction 79
Topical and transdermal preparation for erectile dysfunction 79
Hypogonadism in the male 80
Topical testosterone 80
Women's health 82
Female sexual arousal disorder 82
Menopause 82
Hormone replacement therapy for menopause 83
Effect of transdermal estradiol on bone density 84
Transdermal PTH for postmenopausal osteoporosis 85
Transdermal testosterone for low libido in postmenopausal women 85
Breast disorders 85
Dysmenorrhea 85
Female infertility 86
Contraception 86
Female contraception 86
Ortho Evra™ 87
BAY86-5016 87
Male contraception 88
Transdermal progestin plus testosterone 88
Cancer 88
Nanoemulsion-based delivery of caffeine for skin cancer 88
Transcutaneous electroporation for anticancer drugs 88
Transdermal drug delivery for prostate cancer 89
Transdermal nitroglycerine for prostate cancer 89
Transdermal estradiol gel for prostate cancer 89
Transdermal drug delivery for breast cancer 90
Afimoxifene topical gel for breast cancer 90
Pain 90
Relief of pain associated with minor medical procedures 90
Transdermal LidodermÒ for postherpectic neuralgia 90
Nonsteroidal antiinflammatory drugs 91
Topical NSAIDs 91
Transdermal ketoprofen 92
Topical opioids 93
Cancer pain 93
Transdermal fentanyl 93
Transdermal nitroglycerine as an adjuvant to opioids 94
Transdermal buprenorphine 95
Chronic pain of non-malignant origin 95
Transdermal local anesthetics 95
Postoperative pain 96
Transdermal fentanyl for the management of postoperative pain 96
Fibromyalgia 96
Nausea and vomiting 96
Motion sickness 96
Postoperative vomiting 97
Chemotherapy-induced nausea and vomiting 97
Antiaging strategies 97
Smoking cessation 98
Transdermal nicotine replacement 98
Other methods of nicotine replacement 99
Other treatments for smoking cessation 99
Miscellaneous uses of transdermal drug delivery 99
Chronic fatigue syndrome 99
Topical androgenic steroid therapy 100
Overactive bladder and urinary incontinence 100
Transdermal oxybutynin 100
Viral infections 100
Transdermal nanoparticles for immune enhancement in HIV 101
Transdermal gene therapy 101
Transdermal delivery of plasmid DNA by electroporation 102
Transdermal antisense therapy 102
Transdermal vaccination 103
The skin as an immune organ 103
Technologies for transdermal vaccination 103
Dermal microinjection technology for delivery of vaccines 103
Electroporation for administering DNA vaccines 103
Intradermal delivery of cancer vaccines by adenoviral vectors 104
Needle free delivery of vaccines 104
Transcutaneous immunization 105
Applications of transdermal vaccination 105
HIV/AIDS vaccination by topical application 105
Transdermal DNA influenza vaccine 106
Transdermal Ab vaccination for Alzheimer's disease 106
Transdermal vaccination for traveller's diarrhoea 106
Transdermal neutraceuticals 107
Complications of transdermal therapy 107
Adverse effects of drugs 107
Overdose effect 108
Skin complications 108
4. Markets for Transdermal Drug Delivery 109
Introduction 109
Global markets for drug delivery 109
Geographical distribution of transdermal drug delivery markets 110
Emerging transdermal drug delivery markets in Asia 110
Transdermal technology markets in therapeutic areas 110
Angina pectoris 111
Attention deficit hyperactivity disorder 111
Erectile dysfunction 111
Hypertension 112
Pain therapeutics 112
Parkinson's disease 112
Smoking cessation 112
Transdermal hormone replacement therapy for menopause 112
Transdermal testosterone replacement therapy for hypogonadism in the male 113
Transdermal contraceptive market 113
Markets according to transdermal technologies 113
Marketing strategies for transdermal drug delivery 114
Marketing advantages of transdermal drug delivery 114
Unmet needs in transdermal drug delivery 115
Future prospects of transdermal drug delivery 116
Prospects of transdermal delivery for drugs coming off patents 116
Transdermal delivery of cosmetics 117
5. Companies involved in transdermal drug delivery 119
Profiles of companies 119
1-800-Patches Inc 119
3M Drug Delivery Systems 120
Abbott Laboratories 122
Abeille Pharmaceuticals Inc 123
Acino AG 124
Acrux Ltd 125
Aderis Pharmaceuticals 127
Adherex Technologies Inc 128
Agile Therapeutics Inc 129
AllTranz Inc 130
AlphaRx Inc 131
Altea Therapeutics 132
ALZA 133
Amarin Technologies SA 134
Anesiva Inc 135
An-eX Analytical Services Ltd 136
Antares Pharma Inc 137
Apricus Biosciences Inc 139
Ascend Therapeutics Inc 141
Auxilium Pharmaceuticals Inc 142
Bayer Pharma AG 143
BD (Becton, Dickinson and Company) 144
Bentley Pharmaceuticals Inc 145
BHR Pharma LLC 146
BioSante Pharmaceuticals Inc 147
Biovail Corporation 148
Biovalve Technologies Inc 149
Birch Point Medical 150
Cellegy Pharmaceuticals Inc 151
Celtic Pharma Management LP 152
Cerimon Pharmaceuticals Inc 153
Chrono Therapeutics Inc 154
CollaGenex Pharmaceuticals Inc 155
Connetics Australia Pty Ltd 156
Connetics Corporation 157
Corium International Inc 158
Crospon Ltd 159
Cyto Pulse Sciences Inc 160
DBV Technologies 161
Dermatrends Inc 162
Dharma Therapeutics Inc 163
Dow Pharmaceutical Sciences 164
DURECT Corporation 165
Echo Therapeutics 166
Elan Corporation Plc 167
Embil Pharmaceuticals 168
Empi 169
Encapsulation Systems Inc 170
Endo Pharmaceuticals Inc 171
EpiCept Corporation 172
ESBA Laboratories Inc 173
Genesis Medical Ltd 174
GlaxoSmithKline 175
Gruenenthal GmbH 176
Helix BioPharma Corporation 177
Hexal AG 178
Hisamitsu Pharmaceutical Co Inc 179
Ichor Medical Systems Inc 180
IDEA AG 181
IGI Inc 182
ImaRx Therapeutics Inc 183
Inovio Biomedical Corporation 184
Intercell AG 185
Interstitial NS 186
Iomed Inc 187
Janisys Ltd 188
Johnson & Johnson 189
Laboratoires Pierre Fabre SA 190
Labtec GmbH 191
Lacer SA 192
LAM Pharmaceutical Corp 193
Lavipharm Corporation 194
LecTec Corporation 195
LOHMANN Therapie-Systeme AG 196
MedPharm Ltd 197
Merck KG aA 198
MIKA Pharma GmbH 199
Mylan Laboratories Inc 200
NanoCyte Inc 201
NanoPass Technologies Ltd 202
Nanotechnology Victoria Ltd 203
NB Therapeutics Inc 204
Nemaura Pharma Limited 205
NeurogesX Inc 206
Nitto Denko Corporation 207
NOF Corporation 209
Nometics Inc 210
Norwood Abbey Limited 211
Novagali Pharma SA 212
Novartis 213
Novavax Inc 214
Novel Therapeutic Technologies Ltd 215
Noven Pharmaceutical Inc 216
NuPathe Inc 218
Nuvo Research Inc 219
OBJ Ltd 220
Optimags GmbH 221
Pfizer Pharmaceutical Group 222
Phosphagenics Ltd 223
Polytherapeutics Inc 224
PowderMed Ltd 225
Procter & Gamble Pharmaceuticals Inc 226
ProEthic Pharmaceuticals Inc 227
ProStrakan Group plc 228
pSivida Corporation 229
Purdue Pharma LP 230
Rottapharm 231
Schering-Plough Corporation 232
Somerset Pharmaceutical 233
Strategic Science & Technologies Inc 234
Teikoku Pharma USA Inc 235
Ther-Rx Corporation 236
Transcu Ltd 237
Transdel Pharmaceuticals Inc 238
TransDerm Inc 239
TransDermal Technologies Inc 240
TransDermics Ltd 241
TransPharma Medical Ltd 242
UCB Pharma 244
United Pharmaceuticals 245
Vaso Active Pharmaceuticals 246
Vaxin Inc 247
Vyteris Inc 248
Watson Pharmaceuticals 249
Zars Inc 250
Zosano Pharma Inc 251
Collaborations 252
6. References 257
Tables
Table 1?1: Historical landmarks in the development of transdermal drug delivery 13
Table 1?2: Transdermal vs oral and intravenous drug delivery 15
Table 2?1: Technologies for transdermal drug delivery 19
Table 2?2: Chemical enhancers of skin penetration 24
Table 2?3: Drug-in-adhesive versus reservoir type of transdermal patch 29
Table 2?4: Companies developing transdermal patches for drug delivery 30
Table 2?5: Companies with technologies for drug delivery by iontophoresis 38
Table 2?6: Companies involved in electroporation-based drug delivery 41
Table 2?7: Companies developing microneedles for transdermal drug delivery 50
Table 2?8: Comparison of transdermal drug delivery systems 56
Table 3?1: Approved transdermal products 61
Table 3?2: Transdermal drugs in clinical trials or approval process 63
Table 4?1: Worldwide drug delivery market growth 2011 to 2021 109
Table 4?2: Transdermal drug delivery markets for geographical regions 2011 to 2021 110
Table 4?3: Potential therapeutic markets for transdermal products 2011-2021 111
Table 4?4: Markets according to transdermal technologies 113
Table 4?5: Marketing strategies based on transdermal drug delivery technologies 114
Table 5?1: Collaborations in transdermal drug delivery 252
Figures
Figure 1?1: Basic structure of the skin 14
Figure 1?2: Events governing transcutaneous drug absorption 17
Figure 2?1: Basic structure and function of transdermal drug delivery systems 29
Figure 2?2: A schematic view of electroporation 34
Figure 2?3: Depiction of breakdown of the stratum corneum during electroporation 35
Figure 2?4: A schematic drawing of Iontophoresis 36
Figure 2?5: SonoPrep ultrasonic skin permeation 44
Figure 2?6: A schematic drawing of the microneedle patch 47
Figure 3?1: Oral versus transdermal administration of a drug in Parkinson's disease 71
Figure 4?1: Unmet needs in transdermal drug delivery 116
To order this report:
Drug Delivery Technology Industry: Transdermal Drug Delivery - Technologies, Markets, and Companies
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article